Výsledky vyhledávání

Association of proton pump inhibitors with renal adverse events in non-small cell lung cancer patients treated with PD-1 Inhibitor (APPIANI Study): study protocol for a randomized, assessor- blinded, controlled clinical trial

Autor: Xiaodie Mu, Aihua Wu, Peiyao Ling, Hua Zhou, Min Yang

Introduction: PD-1 inhibitor, an immune checkpoint inhibitor (ICI), is currently the standard first-line treatment for advanced non-small cell lung cancer (NSCLC). Immune-related adverse effects (irAEs), on the other hand, limit their use. Acid-suppr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a151d1eb8cda2720d1976eeaf75c2ed0
https://doi.org/10.21203/rs.3.rs-1601633/v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání